Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Progress in corticotropin-releasing factor-1 antagonist development Zorrilla EP; Koob GFDrug Discov Today 2010[May]; 15 (9-10): 371-83Corticotropin releasing factor (CRF) receptor antagonists have been sought since the stress-secreted peptide was isolated in 1981. Although evidence is mixed concerning the efficacy of CRF(1) antagonists as antidepressants, CRF(1) antagonists might be novel pharmacotherapies for anxiety and addiction. Progress in understanding the two-domain model of ligand-receptor interactions for CRF family receptors might yield chemically novel CRF(1) receptor antagonists, including peptide CRF(1) antagonists, antagonists with signal transduction selectivity and nonpeptide CRF(1) antagonists that act via the extracellular (rather than transmembrane) domains. Novel ligands that conform to the prevalent pharmacophore and exhibit drug-like pharmacokinetic properties have been identified. The therapeutic utility of CRF(1) antagonists should soon be clearer: several small molecules are currently in Phase II/III clinical trials for depression, anxiety and irritable bowel syndrome.|Animals[MESH]|Anti-Anxiety Agents/administration & dosage/pharmacology[MESH]|Antidepressive Agents/administration & dosage/pharmacology[MESH]|CRF Receptor, Type 1[MESH]|Corticotropin-Releasing Hormone/administration & dosage/*analogs & derivatives/pharmacology[MESH]|Disease Models, Animal[MESH]|Drug Delivery Systems/*methods[MESH]|Drug Discovery/*methods[MESH]|Drug Evaluation, Preclinical[MESH]|Drugs, Investigational/*administration & dosage/pharmacology[MESH]|Humans[MESH]|Ligands[MESH]|Molecular Structure[MESH]|Patents as Topic[MESH]|Peptides/*administration & dosage/pharmacology[MESH]|Receptors, Corticotropin-Releasing Hormone/*antagonists & inhibitors[MESH]|Substance-Related Disorders/drug therapy[MESH] |
